BioLineRx to Present GLIX1 Preclinical Efficacy and Phase 1/2a Trial Design at EANO 2026
BLRX is trading near its 52-week low of $2.15 (3.3% above the low) on light trading volume (0.4× avg).
Summary
BioLineRx and Hemispherian will present GLIX1 preclinical efficacy data and Phase 1/2a trial design at EANO 2026, with a mini-oral highlighting potent anti-tumor activity in orthotopic glioblastoma models.
Key Events · Product Development and Regulatory · BLRX
-
GLIX1 Preclinical Data Accepted for Oral Presentation
Two GLIX1 abstracts accepted at EANO 2026, including a mini-oral on September 25, 2026, featuring preclinical efficacy in orthotopic glioblastoma models.
-
Dose-Dependent Anti-Tumor Activity in GBM Models
Oral GLIX1 (75 mg/kg QD to 1000 mg/kg BID) produced dose-dependent tumor growth inhibition and survival benefit in two orthotopic GBM xenograft models (SNB19 and U87-MG), with activity at the lowest dose tested.
-
CNS Penetration Confirmed
GLIX1 achieved brain exposures at 68-85% of plasma levels in mice, supporting blood-brain-barrier penetration for glioblastoma treatment.
-
Phase 1/2a Trial Design Presented
Open-label, multicenter, first-in-human trial using BOIN design across up to 5 dose levels in up to 30 patients with WHO grade 3/4 glioma (≤2 prior therapy lines); actively enrolling at four US academic institutions (NCT07464925).
Analysis · BLRX · Life Sciences
At EANO 2026 (September 24-27, Rome), BioLineRx and Hemispherian will present two GLIX1 abstracts, including a mini-oral on preclinical efficacy in orthotopic glioblastoma models. The data show dose-dependent tumor growth inhibition and survival benefit across two GBM xenograft models, with brain exposure at 68-85% of plasma levels. The Phase 1/2a trial design is also being presented, with enrollment actively ongoing. This matters because GLIX1 is BioLineRx's lead asset and the company is under going-concern pressure with only $13.1 million in cash as of Q2 2026 — positive preclinical data and an active clinical trial are critical to attracting the financing needed to extend its runway.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLRX was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5M. The 52-week trading range was $2.15 to $4.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.